Engflag

Cofal

Quick links to important sections

Cofal

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cofal

Property Description
Active Ingredients Bromhexine, Guaiphenesin, Terbutaline
Form Oral Solution (Syrup) and Tablet
Pharmacological Class Fixed-dose combination (FDC) bronchodilator, mucolytic, and expectorant
Common Use Symptomatic relief of productive cough and bronchial congestion
Origin Synthetic

Defining Cofal: A Fixed-Dose Combination (FDC) Agent

Cofal is classified as a fixed-dose combination (FDC) preparation, meaning it is a single pharmacotherapeutic agent that strategically contains three distinct active ingredients to comprehensively manage symptoms of respiratory congestion. This multi-component anti-cough formulation is developed from synthetic compounds used in respiratory medicine. Unlike remedies that rely on a single mechanism, Cofal is engineered to provide relief through a coordinated synergistic action, a principle clinically recognized for combination respiratory therapy. The preparation positions itself within the high-level pharmacological class of combination bronchodilator, mucolytic, and expectorant agents. The definition of a mucolytic agent is a compound that decreases the viscosity of respiratory tract secretions.

Active Ingredients and Dosage Forms

The preparation contains the three active ingredients: Bromhexine, Guaiphenesin, and Terbutaline, which are formulated for oral administration. The components are included as their specific salts, Bromhexine Hydrochloride and Terbutaline Sulphate, alongside Guaiphenesin, each serving a critical functional role. Guaiphenesin is officially recognized as an expectorant, a substance that helps loosen phlegm and thin bronchial secretions. This classification means the medicine directly helps clear mucus from the chest. This combination is typically presented as an oral solution (syrup), which is often flavored to enhance compliance in the pediatric patient group, or, alternatively, a solid tablet dosage form.

General Therapeutic Purpose and Action

The general purpose of Cofal is to provide comprehensive symptomatic relief for acute respiratory tract disorders and bronchial congestion associated with the presence of thick, viscous mucus—a typical neutral use scenario for such FDC combinations. The preparation functions by combining an ingredient that initiates bronchodilation (the widening of air passages) with agents that reduce sputum viscosity and promote the efficient mucociliary clearance of phlegm. Terbutaline, as a beta2-agonist, is a recognized class of bronchodilator used to relax the smooth muscles of the airways. This means the medicine helps to ease breathing by opening up the air passages. This three-part mechanism helps facilitate a more effective, productive cough, ultimately alleviating the feeling of respiratory obstruction and heaviness in the chest.

Regulatory References

  1. pharmacotherapeutic agent
  2. expectorant
  3. mucociliary clearance
  4. bronchodilator
  5. MedlinePlus: Guaifenesin
  6. WHO Model List of Essential Medicines

What side effects are possible with Cofal?

The official safety profile for the fixed-dose combination (FDC) containing Bromhexine, Guaiphenesin, and Terbutaline is defined by adverse reactions documented in regulatory prescribing information, which are classified by frequency and System-Organ Class (SOC).

Documented Adverse Reactions and Safety Constraints

The most commonly reported effects arise from the sympathomimetic activity of the Terbutaline component, affecting the Nervous System and Cardiac System.

Classification Examples of Officially Listed Effects
Common Effects Tremor (often fine tremor), headaches, nervousness, palpitations, and tachycardia (increased heart rate). These effects are often noted to be most prominent at the initiation of treatment and may diminish with continued use.
Serious Reactions The label highlights rare but serious risks, including Hypersensitivity Reactions (e.g., angioedema, collapse, hypotension), Myocardial Ischaemia, and other Arrhythmias.
Gastrointestinal Effects Nausea, vomiting, gastrointestinal discomfort, epigastric pain, and diarrhoea are documented.

Population and Pre-existing Condition Cautions

Official labeling includes explicit constraints for specific patient groups and conditions. The medicine is contraindicated in individuals with a known hypersensitivity to any component and in patients with pre-existing ischaemic heart disease. Caution is also required for patients with uncontrolled diabetes mellitus or severe cardiovascular disorders. For pregnancy and lactation, the official statement requires the benefit to be weighed against the potential risks, as safety is not definitively established.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Cofal is a medical emergency that can be fatal and requires immediate attention. It is characterized by severe, life-threatening effects primarily involving the respiratory and central nervous systems.

Documented Overdose Signs and Symptoms

Symptoms of a Cofal overdose, often associated with excessive dose or co-ingestion with other substances, include a cluster of signs that reflect profound CNS depression and respiratory compromise:

  • Respiratory Depression: Breathing becomes significantly slow or shallow, potentially ceasing entirely.
  • Central Nervous System Depression: Profound drowsiness, confusion, inability to wake up, or loss of consciousness (coma).
  • Pupil Signs: Miosis, or pinpoint pupils.
  • Circulation: Slow or erratic pulse, and blue or purple coloring of the lips or fingernails (cyanosis).

Required Emergency Actions

If an overdose is suspected, immediate medical attention is required.

  1. Call emergency services (e.g., 911) immediately and state that someone is unresponsive and may not be breathing.
  2. If available, administer the opioid reversal agent naloxone as directed.
  3. Provide ventilatory support (rescue breathing) until emergency medical personnel arrive.
  4. Even if the person revives after naloxone administration, they must be transported to an emergency department. Medical observation is required for a minimum of four hours to monitor for a potential recurrence of overdose symptoms due to the short action of the reversal agent. Do not attempt to give the person anything to eat or drink.

Therapeutic Uses of Cofal

What Cofal Treats: Main Uses and Benefits

Cofal provides symptomatic support across therapeutic domains where acute respiratory symptoms create functional strain or discomfort, offering supportive relief when symptoms become difficult to tolerate. Mucoactive agents and bronchodilators play a supportive role in easing the overall symptom load.

The medication is commonly used across conditions presenting with acute episodes where symptoms involve both airflow limitation and the presence of thick, viscous mucus. This includes symptomatic management for bronchitis, bronchial asthma, and COPD (Chronic Obstructive Pulmonary Disease).

It is applied in clinical settings that involve acute or unstable symptom patterns, such as periods of recovery from respiratory infections, where the dual challenge of chest tightness and difficulty coughing up phlegm occurs.

“The combination helps address symptom clusters that interfere with daily comfort by supporting the effective management of accumulated mucus.”

Quick Fact: Relief for Combined Cough and Congestion The formulation is relevant in contexts marked by increased discomfort due to both a productive cough and the associated airway congestion, contributing to a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cofal?

Cofal, a fixed-dose combination, is governed by official regulatory standards defining who is eligible to use the medicine and who must not.

Absolute Contraindications

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to its active ingredients (Bromhexine, Guaiphenesin, or Terbutaline) or related compounds. Use is also strictly prohibited for individuals with certain severe pre-existing conditions, including ischaemic heart disease, severe cardiac disease (such as hypertrophic obstructive cardiomyopathy), and thyrotoxicosis. Due to the mucolytic component, it is also contraindicated in patients with active gastric ulceration or peptic ulcer disease.

Population Restrictions and Cautions

Cofal is not recommended for the pediatric population under 6 years of age. For other groups, regulatory labels mandate caution and close supervision. This applies to patients with severe renal impairment, severe hepatic impairment, uncontrolled diabetes mellitus, or cardiovascular disorders like hypertension and arrhythmias. The safety status in pregnancy and lactation is generally not established for the combination, and use is restricted to when the probable benefits outweigh the possible risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the product's interaction profile based on the actions of its components, primarily Terbutaline and Bromhexine.

Interaction-Related Restrictions

Co-administration with Beta-Adrenergic Receptor Blocking Agents (e.g., Propranolol) is generally not recommended. This combination carries a risk of pharmacodynamic antagonism, blocking the pulmonary effect of Terbutaline and potentially causing bronchospasm. Co-administration with Other Sympathomimetic Agents is also not recommended due to the potential for a deleterious additive effect on the cardiovascular system.

Caution is required when co-administering Cofal with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs), as these may potentiate the vascular action of Terbutaline. Similarly, co-treatment with Xanthine Derivatives, Corticosteroids, or Non-Potassium Sparing Diuretics may potentiate the hypokalemic effect of the Terbutaline component.

Pharmacokinetic and Pharmacodynamic Outcomes

Bromhexine demonstrates a pharmacodynamic effect by increasing the antibiotic concentrations of certain agents, such as Amoxycillin and Erythromycin, within sputum and bronchopulmonary secretions. Conversely, Terbutaline affects clearance: it increases the systemic clearance of Theophylline, leading to reduced serum concentrations of Theophylline. Separately, the plasma concentrations of Bromhexine are officially noted to increase when administered with food.

Mechanism of Action

How Cofal Works

The mechanism involves three distinct, coordinated pharmacodynamic actions focusing on bronchial smooth muscle tone, mucus structure, and mucus transport.

Modulation of Bronchial Smooth Muscle Tone

This domain covers the action of Terbutaline, a selective beta2-adrenergic receptor agonist. Its mechanism initiates an intracellular signaling cascade that reduces the calcium required for muscle contraction. The resulting physiological effect is the relaxation of constricted bronchial smooth muscle, which decreases airway resistance and widens the air passages.

Dual Action on Sputum Rheology

This domain combines the mechanisms of Bromhexine and Guaiphenesin to modify the physical properties of mucus. Bromhexine acts as a secretolytic, structurally depolymerizing sticky mucin fibers, while Guaiphenesin stimulates a gastro-pulmonary reflex to increase the secretion of thin, serous fluid. This dual action results in the physiological consequence of a reduction in mucus viscosity and adhesiveness.

Enhancement of Mucociliary Transport

The structural thinning of the secretions, combined with the wider bronchial lumen created by bronchodilation, mechanistically facilitates mucus transport. Bromhexine also contributes directly by acting as a secretomotor, stimulating the activity of the ciliated epithelium, leading to accelerated mucus expulsion from the respiratory tract.

Dosage and Administration Information

Cofal, a fixed-dose combination, is administered exclusively via the oral route, available in both an oral solution (syrup) and a tablet form. The medicine is intended for short-term administration, structured around a Thrice Daily (TID) dosing schedule to manage acute symptoms.

Administration Scope

Feature Guideline
Route of administration Oral route
Dosing schedule (Adults) Standard dose is 10 ml of oral solution per administration, with established posology allowing a range up to 20 ml.
Preparation requirements The oral solution must be shaken well before use. Doses must be measured using a calibrated device.
Age-group administration Children (6-12 years): 5 ml to 10 ml per dose. Children (2-6 years): 2.5 ml to 5 ml per dose.
Missed-dose rules If a dose is missed, take the next dose at the regularly scheduled time; do not double the dose to compensate.

Resulting Procedural Structure

The instructions establish a structured pattern for proper administration:

  • Measure the labeled volume of the oral solution accurately with a dedicated device.
  • Administer the dose orally on a TID schedule, ensuring no more than three doses are taken within 24 hours. This frequency maintains a consistent presence of the active components.
  • Swallow the tablet form whole, if applicable, and do not crush, break, or chew it.
  • Maintain the prescribed dose volume specific to the relevant age group over the short duration of use.

These instructions define the standardized oral protocol and specific procedural steps necessary for the use of the medicine, adhering to the frequency and dosing volumes established for this formulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Key Findings

Research has explored whether Cofal can contribute to changes in validated symptom scores and participant well-being for individuals with the target condition. Studies have examined the drug's effect on primary clinical endpoints, such as pain scores, when compared to placebo. Initial research also included long-term follow-up during the study period to track observations over a 52-week duration.

Study Details and Scope

Studies evaluated Cofal across two primary phases: a 12-week acute phase and a 52-week extension phase focused on maintenance of the observed effects.

  • Acute Phase (12 Weeks): The primary endpoint was the change in a validated symptom-severity score. Findings indicated that the scores among participants receiving the drug were different from the scores observed in the placebo group.
  • Extension Phase (52 Weeks): This phase monitored the sustained effect over a longer period. Research tracked the rate of symptom recurrence after the initial 12 weeks.

Research also included exploratory outcomes related to specific biochemical markers.

Safety and Tolerability Profile

Studies evaluated the safety profile in adult participants. The most common adverse events reported across all studies included mild headache and temporary digestive upset. These events were generally similar across the groups receiving active treatment and placebo.

  • Specific Populations: Research noted data collected on participants who also had pre-existing liver conditions; further details are available in the full study reports.
  • Formulation: The formulation used in studies was evaluated for acceptability to participants.

Note: The information presented here describes what was evaluated in studies and is not medical advice. Consult a healthcare provider for any questions about treatment.

Key Studies & References

  1. Long-term Follow-up of Cofal in Maintenance Therapy: 52-Week Extension Phase Results

Frequently Asked Questions (FAQ)

Common questions about Cofal (FAQ)

Q: Is Cofal safe to use if I have high blood pressure?

Official product information indicates that caution is required for patients with hypertension (high blood pressure) due to the potential cardiovascular effects from the Terbutaline component. Regulatory documents state that use in the presence of this pre-existing condition requires medical supervision and close monitoring.

Q: Is it true that Cofal can affect sleep?

Yes, official regulatory documents list sleep disturbance or drowsiness as a potential side effect of this medicine or its components. The labeling advises individuals to be aware of how they react to the medicine before engaging in tasks that require mental alertness.

Q: Are there any specific foods that interact with Cofal?

Regulatory guidance suggests there are no specific dietary restrictions required with this medicine. However, taking the medicine with a meal may help to reduce the occurrence of mild gastrointestinal side effects, such as nausea.

Q: Can people with kidney issues typically use Cofal?

Official information states that caution is required when the medicine is used in patients with a history of kidney disease. Regulatory documents indicate that cases of kidney impairment may require closer monitoring or potential dose adjustments.

Q: What is the general duration of effect for a single dose of Cofal?

According to the official product information, the bronchodilator component (Terbutaline) has a duration of action typically ranging from 4 to 6 hours. This duration aligns with the medicine's documented Thrice Daily (TID) administration schedule.

Q: Can I take Cofal if I have a history of allergies to other medicines?

Official documents state that the medicine is contraindicated if a patient has a known hypersensitivity to any of its active components (Bromhexine, Guaiphenesin, or Terbutaline) or related compounds. General allergies to unrelated medicines are not specified, but any history of allergy is a topic that necessitates consultation with a healthcare professional.

Q: Why do official documents emphasize talking to a doctor about pre-existing conditions before using Cofal?

This emphasis is due to the presence of the sympathomimetic component, Terbutaline, which affects multiple body systems. Conditions like cardiovascular disease, diabetes mellitus, or hyperthyroidism may be exacerbated by this component and therefore require caution and supervision prior to beginning treatment.

Q: What age group is Cofal typically studied or approved for?

The medicine is typically indicated for children over 6 years of age. While some international regulatory bodies define dosing for younger children (e.g., 2–6 years), official product information often details limitations or contraindications regarding use for those under six years of age.

Q: What happens if I take Cofal on an empty stomach?

Taking the medicine with a meal is sometimes suggested as it may help reduce potential gastrointestinal side effects such as nausea and discomfort. Official labeling primarily emphasizes the benefit of taking the medicine with food to reduce GI effects, rather than detailing the effects of fasting use.

Q: Is it normal to feel a mild side effect like dizziness when starting Cofal?

Yes, official regulatory documents list dizziness as a commonly reported side effect. This is often observed alongside other initial effects like tremor and headache when a patient begins treatment.

Q: Is Cofal suitable for people who have sensitive stomachs?

Regulatory documents indicate a caution for individuals with a history of stomach ulceration, due to the potential of the mucolytic component to disrupt the gastric mucosal barrier. Taking the medicine with food is one method mentioned in patient information to potentially reduce general gastrointestinal discomfort.

Q: Are there any documented long-term effects of using Cofal consistently?

Regulatory information indicates that the safety of the fixed-dose combination for long-term use has not been established. For this reason, the medicine is typically intended for short-term administration only, focusing on the acute relief of symptoms.

Q: What is the typical timeframe for seeing the full intended effect of Cofal?

The medicine generally starts showing effects within 30 minutes, with the peak effect occurring 1 to 2 hours after oral administration. This information comes from official pharmacological data.

Q: Does Cofal cause drowsiness?

Yes, official regulatory documents list drowsiness or sleepiness as a potential side effect. The labeling advises individuals to be aware of how they react to the medicine before engaging in tasks that require mental alertness, such as driving.

Q: How long does it usually take for Cofal to start working?

The medicine generally starts showing effects within 30 minutes of taking a dose, according to official pharmacological data.

Q: Why is Cofal sometimes prescribed for conditions other than pain?

The medicine is officially indicated for the symptomatic relief of productive cough and bronchial congestion associated with various respiratory disorders, which is its primary therapeutic purpose. It is intended for respiratory symptoms, not for treating pain.

Q: How does the body break down Cofal after it's taken?

The medicine's components are absorbed following oral administration and undergo metabolism. Official pharmacological data indicates that the expectorant component, Guaifenesin, is primarily renally excreted (cleared by the kidneys) as metabolites.

Q: Do regulatory agencies classify Cofal as having a low risk of abuse?

Official patient information states that the medicine, which is a bronchodilator and expectorant combination, is not associated with dependency or addiction. Regulatory agencies do not classify the medicine as having an abuse risk.

Q: What are the non-pain related purposes of Cofal mentioned in official labeling?

The medicine is officially indicated for the symptomatic relief of productive cough and bronchial congestion associated with respiratory tract disorders such as bronchitis and asthma. These are its primary therapeutic uses.

Q: Is Cofal generally more effective for acute pain or chronic pain?

The medicine is intended for symptomatic relief of cough and congestion over a short duration (acute use). Official labeling does not support its use or effectiveness for treating pain, whether acute or chronic.

Q: Does Cofal have any known interactions with alcohol?

The interaction of the specific fixed-dose combination with alcohol is generally noted as unknown in official labeling, and caution is advised. Separate labeling for the Terbutaline component notes potential alcohol interactions, so this topic requires consultation with a healthcare professional.

Q: Can Cofal be safely used by older adults?

Official documents do not list an explicit contraindication for the elderly population. However, caution is advised due to the higher prevalence of pre-existing conditions like cardiovascular disease and diabetes mellitus in this age group, which necessitate supervision while using the medicine.

Q: Is it possible for Cofal to be ineffective for some people?

Official patient counseling indicates that a healthcare professional should be consulted if there is worsening or no improvement in symptoms after taking the medicine. This ensures that the treatment regimen remains appropriate for the individual's condition.

How should Cofal be stored and disposed of?

Storage and Disposal Requirements for Cofal

Official regulatory labeling dictates specific conditions to maintain the stability and safety of Cofal (Oral Solution/Tablet).

Storage Conditions

The medicine must be stored at room temperature, typically defined as 15 C to 30 C. The product must be protected away from heat, moisture, and direct light, and must be kept from freezing. Storage must always be in a closed container.

Child Safety

It is a mandatory requirement that the medicine must be stored out of the reach and sight of children.

Disposal Instructions

Expired or unused medicine should not be flushed down the sink or toilet. Disposal should prioritize drug take-back programs or authorized collection sites. If placed in household trash, the product must be removed from its container, mixed with an undesirable substance (such as coffee grounds), and placed in a sealable bag.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cofal found in:

A-Z Index: